VRUS Related Analyst Ratings
-
Bank of America Initiates Coverage on Pharmasset (VRUS) with a Buy.
-
Baird Maintains an 'Outperform' on Pharmasset (VRUS); Year Ahead is Catalyst-Rich
-
Wedbush Assumes and Initiates Coverage on Several Key Biotech Players in Anti-Viral Space
-
Leerink Swann Maintains an 'Outperform' on Pharmasset (VRUS); Checks Indicate Phase IIb Trial of RG7128 is Progressing Well
-
William Blair Initiates Coverage on Pharmasset (VRUS) with an Outperform
-
Baird upgrades Pharmasset (VRUS) to Outperform
-
UBS Downgrades Pharmasset (VRUS) to Neutral
-
ThinkPanmure Initiates Coverage on Pharmasset (VRUS) with a Buy
-
Roth Capital Starts Pharmasset (VRUS) at Sell
-
Morgan Stanley Initiates Coverage on Pharmasset (VRUS)
-
Cowen & Co Initiates Coverage on Pharmasset (VRUS) with an Outperform
-
Lazard Starts Pharmasset (VRUS) at Buy
-
Lazard Starts Pharmasset (VRUS) at Buy
-
Pacific Growth Starts Pharmasset (VRUS) at Buy
-
Color on Baird Coverage of Pharmasset (VRUS)
-
Baird Initiates Coverage on Pharmasset (VRUS) with a Neutral
-
UBS Upgrades Pharmasset (VRUS) to Buy
-
Merriman Curhan Initiates Coverage on Pharmasset (VRUS) with a Buy
-
UBS downgrades Pharmasset (VRUS) to Neutral
-
JMP Securities Starts Pharmasset, (VRUS) at Outperform
-
Canaccord Adams is recommending 15 names to weather a bad tape: ITRI, HOLX, HANS, ADBE, more...
-
Stifel Nicolaus Downgrades Pharmasset (VRUS) to Hold
-
Susquehanna Initiates Coverage on Pharmasset (VRUS) with a Positive
-
Canaccord Adams added Pharmasset (VRUS) to its Best Idea List
-
UBS Starts Pharmasset (VRUS) with a Buy Rating
-
Stifel Nicolaus Initiates Coverage on Pharmasset (VRUS) with a Buy
-
Banc of America Starts Pharmasset (VRUS) at Buy
Back to VRUS Stock Lookup
